Log in to save to my catalogue

Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multip...

Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multip...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9459263

Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105)

About this item

Full title

Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105)

Publisher

Tokyo: John Wiley & Sons, Inc

Journal title

Cancer science, 2022-09, Vol.113 (9), p.3267-3270

Language

English

Formats

Publication information

Publisher

Tokyo: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

Among patients with PS 2–3 at study enrollment (10 patients each in both arms), the long-term PFS in Arm A also tended to be better compared with that in Arm B. As our eligibility criteria permitted the enrollment of patients with PS 3 only resulting from osteolytic lesions (six patients in Arm A and eight patients in Arm B), rapid responses to tre...

Alternative Titles

Full title

Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105)

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9459263

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9459263

Other Identifiers

ISSN

1347-9032,1349-7006

E-ISSN

1349-7006

DOI

10.1111/cas.15484

How to access this item